OncoSil adds FDA approval to 45.8% revenue growth as U.S. launch approaches

FDA approval opens a controlled U.S. launch

OncoSil Medical Limited (ASX:OSL) has moved from regulatory ambition to commercial execution after securing U.S. Food and Drug Administration Humanitarian Device Exemption approval for its OncoSil device in unresectable, non-metastatic distal cholangiocarcinoma. The approval authorises marketing in the United States as an adjunct to systemic therapy and makes OncoSil the first and only FDA-approved Class III medical device for that cancer indication, according to the company.

Management estimates an annual U.S. patient population of about 1,000 and a potential addressable market of A$80 million. The company has applied to the Centers for Medicare & Medicaid Services for Transitional Pass-Through payment status at a proposed price of US$55,000 per dose. That review remains open: the previously identified 1 January 2027 start date is only a possibility, not a confirmed reimbursement commencement.

The first U.S. rollout will also be narrower than the headline market estimate suggests. FDA conditions limit initial distribution to five academic medical centres participating in a mandatory Post-Approval Study involving 30 patients. OncoSil plans to discuss wider distribution with the FDA after enrolment, while follow-up will continue for approximately 24 months. A second-half FY27 commercial launch therefore rests on both the reimbursement decision and execution of this early clinical access programme.

Revenue growth meets a still-heavy cash burn

Quarterly sales revenue rose 45.8% year on year, pointing to stronger commercial adoption across established markets. Spain has treated its 100th patient across 11 active sites, while Saudi Arabia offers a potentially lower access barrier because eligible Saudi nationals receive fully reimbursed treatment.

The cash data are less straightforward. Customer receipts fell 26.6% year on year to A$0.47 million even as recognised revenue increased, which OncoSil attributed to the timing of invoice collections. The company used A$3.08 million in operating cash during the quarter, including A$1.29 million on research and development, A$1.14 million on staff costs and A$0.72 million on manufacturing and operating costs. Research spending rose mainly because the TRIPP-FFX study was closed out.

A$5.6 million from a institutional funding round would ordinarily be the headline financing event, but in this case it is also the bridge between regulatory approval and launch spending. The September package comprised a A$4 million placement at A$1.00 a share and about A$1.6 million from early option exercises at A$0.90. Cash and equivalents finished the quarter at A$8.72 million, up from A$6.48 million, although the Appendix 4C implies only 2.84 quarters of funding when measured against the latest operating cash outflow. That calculation is based on one quarter and does not capture how launch expenditure may change.

Sydney production moves towards commercial supply

Cyclotek completed three manufacturing validation cycles involving more than 50 device doses, and its Macquarie Park facility received ISO 13485 certification. The site is backed by approximately A$2.1 million of OncoSil-owned specialised equipment and is intended to provide local supply for the Australian and U.S. launches.

The certification removes one important manufacturing hurdle, following the ISO 13485 certification milestone reported earlier in September, but commercial production remains subject to remaining Notified Body approvals. OncoSil is targeting production by the end of the second half of FY27 and expects the facility to support higher capacity, supply-chain resilience and potential manufacturing efficiencies at scale.

Clinical programmes add support for label expansion

Updated TRIPP-FFX results presented at ESMO GI 2026 showed an intention-to-treat local disease control rate of 82.2% and median overall survival of 18.2 months in patients receiving OncoSil plus FOLFIRINOX. A per-protocol analysis reported median overall survival of 21.3 months versus 15.6 months in the chemotherapy-only group. Those figures come from the study analyses described by the company and are being used to support a proposed label expansion, subject to regulatory approval.

The OSPREY real-world registry also produced early signals across 64 patients at 19 European centres, with 12-week local disease control of 91.4% in first-line patients and 77.8% in second-line patients. No Grade 3 or higher adverse device effects were reported in the analysis, and seven patients underwent surgical resection, including five R0 resections. Separately, OncoSil’s participation in the PALACROS consortium through the 120-patient PULSE Phase II study gives it an opportunity to expand evidence without funding an equivalent company-sponsored study; the company estimates the arrangement represents about A$9 million in savings.

The next test is conversion. CMS must decide whether to support the proposed U.S. reimbursement pathway, U.S. centres must activate and enrol the post-approval study, and Australian production still needs its remaining approvals. At the same time, the company will need collections and treatment volumes to catch up with the commercial narrative before the latest capital injection becomes a historical footnote rather than launch capital.